Kala Bio Q1 2021 Earnings Report
Key Takeaways
Kala Pharmaceuticals reported net product revenues of $3.3 million for Q1 2021, with $1.64 million from EYSUVIS sales and $1.63 million from INVELTYS sales. The company's cash position was strong at $156.0 million, projecting a cash runway for at least two years. A new credit facility provides up to $125 million.
Net product revenues reached $3.3 million, with $1.64 million from EYSUVIS and $1.63 million from INVELTYS.
EYSUVIS prescriptions filled exceeded 11,600 between early January and April 23, 2021.
Secured commercial coverage for over 69 million lives, representing approximately 43% of commercially insured lives.
New credit facility provides up to $125 million, extending the projected cash runway to at least two years.
Kala Bio
Kala Bio
Kala Bio Revenue by Segment
Forward Guidance
Kala anticipates that its cash resources as of March 31, 2021, together with anticipated revenue from EYSUVIS and INVELTYS, will enable it to fund its operations for at least two years.